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Severe fever with thrombocytopenia syndrome is an emerg-
ing hemorrhagic fever disease in eastern Asia, caused by a 
tickborne bunyavirus. Of 25 patients hospitalized with this 
disease in China, 100% produced and maintained neutral-
izing antibodies to severe fever with thrombocytopenia syn-
drome virus for the study period of 4 years. 
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever disease in eastern 
Asia (1–3). SFTS is caused by SFTS virus (SFTSV), a 
tickborne bunyavirus that is transmitted through tick bites 
(1,3,4) and person to person by contact with patient blood 
(5,6). Clinically, SFTS is characterized by a sudden onset 
of fever, thrombocytopenia, hemorrhagic tendency, gastro-
intestinal symptoms, and multiple organ dysfunction and a 
high case-fatality rate of 12%–30% (1). SFTSV is a rela-
tively new bunyavirus, and information regarding its neu-
tralizing antibodies is scarce. In this study, we determined 
the prevalence and duration of neutralizing antibodies in 
serum samples of SFTS patients in China.
The Study
For this study, patients with a clinical diagnosis of SFTS 
were those who had fever, thrombocytopenia, or leuko-
penia without another known acute infectious disease; 
patients with laboratory-confirmed SFTS had SFTSV anti-
bodies or RNA detected by ELISA or reverse transcription 
PCR (RT-PCR). Acute-phase (within 2 weeks after onset 
of illness) and convalescent-phase serum samples obtained 
during hospitalization of the patients were tested for total 
antibodies against SFTSV by using a double-antigen sand-
wich ELISA kit (Xinlianxin Biomedical Technology Lim-
ited, Wuxi, China). The study was approved by the ethics 
committee of Shandong University. Informed consent was 
obtained from all participants.
The ELISA plates were coated with recombinant 
SFTSV nucleoprotein (7). Undiluted patient serum sam-
ples were used for ELISA; SFTSV antibodies were de-
tected with horseradish peroxidase–labeled recombinant 
SFTSV protein. Serum samples were considered positive 
for SFTSV when absorbance of the sample was >2.1 times 
that of a negative control at 450 nm (8). Nested RT-PCR 
amplification of the SFTSV RNA large segment (900 bp) 
and small segment (600 bp) have been described previous-
ly (8). PCR products were confirmed to be SFTSV RNA by 
DNA sequencing.
During June 26, 2011–August 26, 2012, a total of 46 
patients were hospitalized and given a clinical diagnosis 
of SFTS in a local hospital in Yiyuan County, Shandong 
Province, China. We confirmed by ELISA or RT-PCR that 
33 (71.7%) of these 46 patients were infected with SFTSV. 
Of the confirmed cases of SFTS, 22 occurred in 2011 and 
were reported previously (8). Two (6.1%) patients with 
confirmed SFTS died.
Among the 31 laboratory-confirmed living patients 
with SFTS, 25 agreed and 6 refused to donate blood sam-
ples for neutralization assay after discharge. Thirteen (52%) 
volunteers were male and 12 (48%) were female; their ages 
ranged from 42 to 75 years (median age 62 years).
Blood samples were obtained from the 25 SFTS vol-
unteers 2 or 3 times during a 4-year period. Serum samples 
were heat inactivated at 56°C for 30 min and diluted in 
2-fold increments from 1:5 to 1:1,280. Each dilution of se-
rum was mixed with an equal volume of solution containing 
SFTSV (1,000 pfu/mL) at 37°C for 1 hour. Culture medium 
was used as a control for serum. Samples were tested by us-
ing the 50% plaque reduction neutralization test (PRNT50). 
The titer obtained is the reciprocal of the highest serum di-
lution that reduces the number of plaques by 50% relative 
to the average number of plaques in viral control wells.
At first, SFTSV does not form clear plaques on Vero 
cells. SFTSV is passaged on Vero cells until plaques are 
clearly visible. Initially, 106 SFTSV is inoculated into cells 
in 1 well of a 6-well plate. When a cytopathic effect is vis-
ible, cells with the cytopathic effect are aspirated with a 
pipette tip and transferred to a new well. A single plaque is 
picked and used for viral stock when the plaques are clearly 
visible on the fifth passage.
To determine the viral titer with a plaque assay, the vi-
ral stock is diluted from 10–2 to 10−6 in 10-fold increments. 
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Each dilution of viral stock is used to infect 2 wells of cells. 
(The negative control contains maintenance medium with-
out virus.) Infected cells are incubated at 37°C in 5% CO2 
for 1 h; then, viral inoculum is replaced with Dulbecco’s 
modified Eagle medium containing 1.5% methylcellulose, 
1% fetal bovine serum, 10 mmol/L HEPES, penicillin (100 
units/mL), and streptomycin (100 µg/mL). Plates are incu-
bated at 37°C in 5% CO2 for 10 d. The monolayer is fixed 
with 4% paraformaldehyde and stained with crystal violet. 
Plaques in each well are counted to determine the plaque-
forming unit.
PRNT50 results showed that all 25 patients developed 
neutralizing antibodies against SFTSV at titers from 20 to 
640; the neutralizing antibodies lasted for the entire study 
period of 4 years (Table). We also performed PRNT90 tests 
for all 25 patients; these showed similar results to PRNT50, 
but the titers were less in extent than those of PRNT50 (data 
not shown). 
In general, the titer of neutralizing antibodies de-
creased over time in all but 2 patients (nos. 5 and 11), who 
had a higher PRNT50 titer in the last year than in the first 
year; this increase may have been caused by reinfection 
with SFTSV. However, our previous studies indicate that, 
in the local area, the incidence of SFTSV infection is <5 
cases/100,000 population and the seroprevalence rate of 
SFTSV in the healthy population is <1% (8–10), suggest-
ing that the chance of reinfection of a patient with SFTSV 
is low. We cannot exclude, however, that these 2 patients 
could have been infected with other phleboviruses that 
have not yet been isolated in China. Serum samples from 2 
healthy persons were also tested for neutralizing antibodies 
as controls; neither of them had any neutralization activity 
against SFTSV.
Conclusions
We found that hospitalized patients with SFTS produced 
long-lasting neutralizing antibodies to SFTSV. We do not 
know the characteristics of the neutralizing antibodies 
against SFTSV, which need to be further investigated. In 
general, neutralizing antigens of bunyavirus are located on 
the viral glycoproteins (11–13). A neutralizing monoclo-
nal antibody to SFTSV is found to bind a linear epitope in 
the ectodomain of glycoprotein Gn of SFTSV. Its neutral-
izing activity is attributed to blockage of the interactions 
between the Gn protein and the cellular receptor (14). The 
limitation of this study is that we obtained SFTS patients’ 
serum samples for only up to 4 years after diagnosis; we do 
not know how long the neutralizing antibodies in patients 
will last.
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Table. Neutralizing antibody titers for convalescent-phase serum 
samples from 25 patients with SFTS, Yiyuan County, Shandong, 
China, 2011–2014* 
Patient no. 
Titer by PRNT50 
First year Second year Third year Fourth year 
1 640 NT 320 80 
2 80 NT 40 80 
3 NT NT 40 40 
4 20 NT 40 40 
5 20 NT 40 40 
6 80 NT 80 20 
7 40 NT 80 40 
8 5 NT 20 40 
9 40 NT 40 20 
10 160 NT 80 80 
11 160 NT 20 80 
12 160 NT 40 40 
13 40 NT 20 NT 
14 NT NT 320 NT 
15 160 NT 160 80 
16 320 NT 40 40 
17 160 NT 40 40 
18 NT NT 80 40 
19 640 NT 160 160 
20 320 80 80 NT 
21 640 320 80 NT 
22 20 20 20 NT 
23 320 80 NT NT 
24 NT 80 40 NT 
25 640 80 160 NT 
*Convalescent-phase serum samples were obtained during the first, 
second, third, and fourth years after discharge of the patients from the 
hospital. NT, no test performed because serum was not available; PRNT50, 
plaque reduction neutralization test indicating the serum titer that reduced 
50% of plaque-forming units of SFTS virus; SFTS, severe fever with 
thrombocytopenia syndrome. 
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